TY - JOUR
T1 - Divergent roles of Plexin D1 in cancer
AU - Vivekanadhan, Sneha
AU - Mukhopadhyay, Debabrata
N1 - Funding Information:
This work was supported by National Institutes of Health grants CA78383 and CA150190 , Florida Department of Health Cancer Research Chair's Fund (FLORIDA #3J-02-04) and Development Grant (MCKENZIE16-PAN) to D. Mukhopadhyay, and the Mayo Clinic College of Medicine and Science to S. Vivekanandhan. The authors thank Nisha C. Durand, PhD, for her editorial help.
Funding Information:
This work was supported by National Institutes of Health grants CA78383 and CA150190, Florida Department of Health Cancer Research Chair's Fund (FLORIDA #3J-02-04) and Development Grant (MCKENZIE16-PAN) to D. Mukhopadhyay, and the Mayo Clinic College of Medicine and Science to S. Vivekanandhan. The authors thank Nisha C. Durand, PhD, for her editorial help.
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/8
Y1 - 2019/8
N2 - Plexin D1 belongs to a family of transmembrane proteins called plexins. It was characterized as a receptor for semaphorins and is known to be essential for axonal guidance and vascular patterning. Mutations in Plexin D1 have been implicated in pathologic conditions such as truncus arteriosus and Möbius syndrome. Emerging data show that expression of Plexin D1 is deregulated in several cancers; it can support tumor development by aiding in tumor metastasis and EMT; and conversely, it can act as a dependence receptor and stimulate cell death in the absence of its canonical ligand, semaphorin 3E. The role of Plexin D1 in tumor development and progression is thereby garnering research interest for its potential as a biomarker and as a therapeutic target. In this review, we describe its discovery, structure, mutations, role(s) in cancer, and therapeutic potential.
AB - Plexin D1 belongs to a family of transmembrane proteins called plexins. It was characterized as a receptor for semaphorins and is known to be essential for axonal guidance and vascular patterning. Mutations in Plexin D1 have been implicated in pathologic conditions such as truncus arteriosus and Möbius syndrome. Emerging data show that expression of Plexin D1 is deregulated in several cancers; it can support tumor development by aiding in tumor metastasis and EMT; and conversely, it can act as a dependence receptor and stimulate cell death in the absence of its canonical ligand, semaphorin 3E. The role of Plexin D1 in tumor development and progression is thereby garnering research interest for its potential as a biomarker and as a therapeutic target. In this review, we describe its discovery, structure, mutations, role(s) in cancer, and therapeutic potential.
KW - Angiogenesis
KW - Cancer
KW - Metastasis
KW - Plexin
KW - Plexin D1
UR - http://www.scopus.com/inward/record.url?scp=85067567623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067567623&partnerID=8YFLogxK
U2 - 10.1016/j.bbcan.2019.05.004
DO - 10.1016/j.bbcan.2019.05.004
M3 - Review article
C2 - 31152824
AN - SCOPUS:85067567623
SN - 0304-419X
VL - 1872
SP - 103
EP - 110
JO - Biochimica et Biophysica Acta - Reviews on Cancer
JF - Biochimica et Biophysica Acta - Reviews on Cancer
IS - 1
ER -